The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 09, 2025

Filed:

Jan. 10, 2020
Applicant:

The University of North Carolina AT Chapel Hill, Chapel Hill, NC (US);

Inventors:

Rihe Liu, Chapel Hill, NC (US);

Gianpietro Dotti, Chapel Hill, NC (US);

Jingjing Li, Chapel Hill, NC (US);

Jiyoung Ahn Morrison, Chapel Hill, NC (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 19/00 (2006.01); A61K 38/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4204 (2025.01); A61K 40/4205 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/2863 (2013.01); A61K 2239/29 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/54 (2023.05); C07K 2317/31 (2013.01); C07K 2317/569 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01);
Abstract

Provided herein are biepitopic or bispecific chimeric antigen receptors. The chimeric antigen receptors comprise a combination of single domain antibody mimics. The single domain antibody mimics may be monobodies, affibodies, or DARPins. The disclosed chimeric antigen receptors may recognize two different epitopes of the same tumor antigen. For example, the chimeric antigen receptor may recognize two different epitopes of HER-2 or EGFR. The disclosed chimeric antigen receptors may recognize two epitopes of two different tumor antigens. For example, the chimeric antigen receptor may recognize HER-2 and EGFR. The disclosed chimeric antigen receptors may be expressed in immune cells for use in cancer immunotherapy.


Find Patent Forward Citations

Loading…